NCT04205357View on ClinicalTrials.gov

Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

October 14, 2022

Study Completion Date

October 14, 2022

Conditions
GliomaGlioblastomaRecurrent Glioblastoma
Interventions
DRUG

Sulfasalazine

Sulfasalazine combined with stereotactic radiosurgery

Trial Locations (1)

5021

Haukeland University Hospital, Bergen

Sponsors

Collaborators (1)

Northwell Health
All Listed Sponsors
collaborator

Norwegian Cancer Society

OTHER

collaborator

Northwell Health

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

University of Bergen

OTHER

collaborator

Helse Stavanger HF

OTHER_GOV

lead

Haukeland University Hospital

OTHER

NCT04205357 - Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter